Download PDF
Dtsch Med Wochenschr 2014; 139(45): 2294-2298
DOI: 10.1055/s-0034-1387355
Übersicht | Review article
Kardiologie
© Georg Thieme Verlag KG Stuttgart · New York

Chronische und akute Herzinsuffizienz – Neue Erkenntnisse und Studien des letzten Jahres

Acute and chronic heart failure – Innovations of the last year and their underlying clinical trials
S. Ewen
1   Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar
,
M. Böhm
1   Klinik für Innere Medizin III, Kardiologie, Angiologie und Internistische Intensivmedizin, Universitätsklinikum des Saarlandes, Homburg/Saar
› Author Affiliations
Further Information

Publication History

12 April 2014

16 October 2014

Publication Date:
28 October 2014 (online)

Also available at
    Permissions and Reprints

Schlüsselwörter

ESC-Richtlinien - akutes Herzversagen - chronisches Herzversagen - erhaltene linksventrikuläre Ejektionsfraktion - pharmakologische Behandlung

Keywords

ESC guidelines - acute heart failure - chronic heart failure - preserved left ventricular ejection fraction - pharmacological treatment
 

  • Literatur

  • 1 Anand IS, Assmann SF, Boineau R et al. Treatment of preserved cardiac function heart failure with an aldosterone antagonist (TOPCAT). NCT00094302 American Heart Association Scientific Sessions 2013; Late Breaking Trial Session, 18.11.2013
    PubMedGoogle Scholar
  • 2 Anker SD, Comin Colet J, Filippatos G et al. Ferric carboxymaltose in patients with heart failure and iron deficiency. N Engl J Med 2009; 361: 2436-2448
    CrossrefPubMedGoogle Scholar
  • 3 Böhm M, Borer J, Ford I et al. Heart rate at baseline influences the effect of ivabradine on cardiovascular outcomes in chronic heart failure: analysis from the SHIFT study. Clin Res Cardiol 2013; 102: 11-22
    CrossrefPubMedGoogle Scholar
  • 4 Böhm M, Swedberg K, Komajda M et al. Heart rate as a risk factor in chronic heart failure (SHIFT): the association between heart rate and outcomes in a randomised placebo-controlled trial. Lancet 2010; 376: 886-894
    CrossrefPubMedGoogle Scholar
  • 5 Boos CJ, Nam M, Camm AJ. Novel oral anticoagulants and stroke prevention in atrial fibrillation and chronic heart failure. Heart Fail Rev 2014; 19: 391-401
    CrossrefPubMedGoogle Scholar
  • 6 Borer JS, Böhm M, Ford I et al. Efficacy and safety of ivabradine in patients with severe chronic systolic heart failure (from the SHIFT study). Am J Cardiol 2014; 113: 497-503
    CrossrefPubMedGoogle Scholar
  • 7 Chatterjee S, Moeller C, Shah N et al. Eplerenone is not superior to older and less expensive aldosterone antagonists. Am J Med 2012; 125: 817-825
    CrossrefPubMedGoogle Scholar
  • 8 Collier TJ, Pocock SJ, McMurray JJ et al. The impact of eplerenone at different levels of risk in patients with systolic heart failure and mild symptoms: insight from a novel risk score for prognosis derived from the EMPHASIS-HF trial. Eur Heart J 2013; 34: 2823-2829
    PubMedGoogle Scholar
  • 9 Edelmann F, Wachter R, Schmidt AG et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 2013; 309: 781-791
    Google Scholar
  • 10 Filippatos G, Farmakis D, Colet JC et al. Intravenous ferric carboxymaltose in iron-deficient chronic heart failure patients with and without anaemia: a subanalysis of the FAIR-HF trial. Eur J Heart Fail 2013; 15: 1267-1276
    CrossrefPubMedGoogle Scholar
  • 11 Fox K, Komajda M, Ford I et al. Effect of ivabradine in patients with left-ventricular systolic dysfunction: a pooled analysis of individual patient data from the BEAUTIFUL and SHIFT trials. Eur Heart J 2013; 34: 2263-2270
    CrossrefPubMedGoogle Scholar
  • 12 Franke J, Wolter JS, Meme L et al. Optimization of pharmacotherapy in chronic heart failure: is heart rate adequately addressed?. Clin Res Cardiol 2013; 102: 23-31
    CrossrefPubMedGoogle Scholar
  • 13 Ganz T, Nemeth E. Hepcidin and iron homeostasis. Biochim Biophys Acta 2012; 1823: 1434-1443
    CrossrefPubMedGoogle Scholar
  • 14 Gheorghiade M, Bohm M, Greene SJ et al. Effect of aliskiren on postdischarge mortality and heart failure readmissions among patients hospitalized for heart failure: the ASTRONAUT randomized trial. JAMA 2013; 309: 1125-1135
    CrossrefPubMedGoogle Scholar
  • 15 Greene SJ, Vaduganathan M, Wilcox JE et al. The prognostic significance of heart rate in patients hospitalized for heart failure with reduced ejection fraction in sinus rhythm: insights from the EVEREST (Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study With Tolvaptan) trial. JACC Heart Fail 2013; 1: 488-496
    CrossrefPubMedGoogle Scholar
  • 16 Groenveld HF, Januzzi JL, Damman K et al. Anemia and mortality in heart failure patients a systematic review and meta-analysis. J Am Coll Cardiol 2008; 52: 818-827
    CrossrefPubMedGoogle Scholar
  • 17 Homma S, Thompson JL, Pullicino PM et al. Warfarin and aspirin in patients with heart failure and sinus rhythm. N Engl J Med 2012; 366: 1859-1869
    CrossrefPubMedGoogle Scholar
  • 18 Homma S, Thompson JL, Sanford AR et al. Benefit of warfarin compared with aspirin in patients with heart failure in sinus rhythm: a subgroup analysis of WARCEF, a randomized controlled trial. Circ Heart Fail 2013; 6: 988-997
    CrossrefPubMedGoogle Scholar
  • 19 Krum H, Shi H, Pitt B et al. Clinical benefit of eplerenone in patients with mild symptoms of systolic heart failure already receiving optimal best practice background drug therapy: analysis of the EMPHASIS-HF study. Circ Heart Fail 2013; 6: 711-718
    CrossrefPubMedGoogle Scholar
  • 20 Lip GY, Ponikowski P, Andreotti F et al. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A joint consensus document from the ESC Heart Failure Association and the ESC Working Group on Thrombosis. Eur J Heart Fail 2012; 14: 681-695
    CrossrefPubMedGoogle Scholar
  • 21 Maggioni AP, Greene SJ, Fonarow GC et al. Effect of aliskiren on post-discharge outcomes among diabetic and non-diabetic patients hospitalized for heart failure: insights from the ASTRONAUT trial. Eur Heart J 2013; 34: 3117-3127
    CrossrefPubMedGoogle Scholar
  • 22 McAlister FA, Wiebe N, Ezekowitz JA et al. Meta-analysis: beta-blocker dose, heart rate reduction, and death in patients with heart failure. Ann Intern Med 2009; 150: 784-794
    CrossrefPubMedGoogle Scholar
  • 23 McMurray JJ, Adamopoulos S, Anker SD et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 2012; 33: 1787-1847
    CrossrefPubMedGoogle Scholar
  • 24 Neuberger HR, Mewis C, van Veldhuisen DJ et al. Management of atrial fibrillation in patients with heart failure. Eur Heart J 2007; 28: 2568-2577
    CrossrefPubMedGoogle Scholar
  • 25 Philipson H, Ekman I, Forslund HB et al. Salt and fluid restriction is effective in patients with chronic heart failure. Eur J Heart Fail 2013; 15: 1304-1310
    CrossrefPubMedGoogle Scholar
  • 26 Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999; 341: 709-717
    Google Scholar
  • 27 Redfield MM, Chen HH, Borlaug BA et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 2013; 309: 1268-1277
    CrossrefPubMedGoogle Scholar
  • 28 Rienstra M, Damman K, Mulder BA et al. Beta-blockers and outcome in heart failure and atrial fibrillation: a meta-analysis. JACC Heart Fail 2013; 1: 21-28
    CrossrefPubMedGoogle Scholar
  • 29 Savard LA, Thompson DR, Clark AM. A meta-review of evidence on heart failure disease management programs: the challenges of describing and synthesizing evidence on complex interventions. Trials 2011; 12: 194
    CrossrefPubMedGoogle Scholar
  • 30 Schowalter M, Gelbrich G, Stork S et al. Generic and disease-specific health-related quality of life in patients with chronic systolic heart failure: impact of depression. Clin Res Cardiol 2013; 102: 269-278
    CrossrefPubMedGoogle Scholar
  • 31 Shah SJ, Heitner JF, Sweitzer NK et al. Baseline characteristics of patients in the treatment of preserved cardiac function heart failure with an aldosterone antagonist trial. Circ Heart Fail 2013; 6: 184-192
    CrossrefPubMedGoogle Scholar
  • 32 Swedberg K, Komajda M, Böhm M et al. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet 2010; 376: 875-885
    CrossrefPubMedGoogle Scholar
  • 33 Swedberg K, Young JB, Anand IS et al. Treatment of anemia with darbepoetin alfa in systolic heart failure. N Engl J Med 2013; 368: 1210-1219
    CrossrefPubMedGoogle Scholar
  • 34 Takimoto E, Champion HC, Li M et al. Chronic inhibition of cyclic GMP phosphodiesterase 5A prevents and reverses cardiac hypertrophy. Nat Med 2005; 11: 214-222
    CrossrefPubMedGoogle Scholar
  • 35 Tavazzi L, Swedberg K, Komajda M et al. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. Eur J Heart Fail 2013; 15: 1296-1303
    CrossrefPubMedGoogle Scholar
  • 36 Tebbe U, Tschope C, Wirtz JH et al. Registry in Germany focusing on level-specific and evidence-based decision finding in the treatment of heart failure: REFLECT-HF. Clin Res Cardiol 2014; 103: 665-673
    CrossrefPubMedGoogle Scholar
  • 37 Zannad F, McMurray JJ, Krum H et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 2011; 364: 11-21
    Google Scholar